AI Portfolio Summary
In 2025 Q4, Omega Fund Management, LLC maintained a portfolio of 12 distinct positions. They heavily accumulated shares in enGene Holdings Inc., increasing their position by 66.5%. Conversely, Omega Fund Management, LLC completely exited their position in enGene Holdings Inc..
Total Positions
12
Quarter
2025 Q4
Top Holding
NUVB (25.3%)
Top 10 Concentration
99.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-12 of 12
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio
|
Healthcare | 25.27% | 14.69% |
#1
4
Prev: #5
|
6.5 | -750,000 | -8.5% |
P
S
|
8,081,089 | $72,406,557 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBOT
BridgeBio Oncol...
|
Healthcare | 14.37% | 17.13% |
#2
1
Prev: #3
|
6.5 | no change | no change |
P
S
|
3,289,661 | $41,186,556 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBNX
Beta Bionics In...
|
Healthcare | 14.00% | 17.16% |
#3
1
Prev: #2
|
5.0 | -603,942 | -31.5% |
P
S
|
1,316,183 | $40,104,096 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 12.95% | 15.66% |
#4
Prev: #4
|
5.5 | no change | no change |
P
S
|
2,204,650 | $37,104,260 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KMTS
Kestra Med Tech...
|
Healthcare | 12.71% | 17.59% |
#5
4
Prev: #1
|
5.0 | -272,302 | -16.5% |
P
S
|
1,373,591 | $36,427,633 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
Upstream Bio In...
|
Healthcare | 12.57% | 11.47% |
#6
Prev: #6
|
4.5 | -30,000 | -2.2% |
P
S
|
1,326,293 | $36,008,855 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
enGene Holdings...
|
Healthcare | 2.76% | 1.62% |
#7
1
Prev: #8
|
4.1 | 350,000 | 66.5% |
P
S
|
876,357 | $7,913,504 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALMS
Alumis Inc.
|
Healthcare | 2.23% | 1.17% |
#8
2
Prev: #10
|
1.9 | no change | no change |
P
S
|
653,223 | $6,375,456 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SANA
Sana Biotechnol...
|
Healthcare | 1.20% | 1.35% |
#9
Prev: #9
|
1.5 | no change | no change |
P
S
|
843,750 | $3,434,063 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMA
ImageneBio, Inc...
|
Healthcare | 1.10% | 1.67% |
#10
3
Prev: #7
|
1.4 | no change | no change |
P
S
|
455,361 | $3,141,991 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REPL
Replimune Group
|
Healthcare | 0.84% | 0.47% |
#11
Prev: #11
|
1.3 | no change | no change |
P
S
|
248,672 | $2,417,092 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGNW
enGene Holdings...
|
Bond/Debt | 0.00% | 0.03% |
Sold All 😨
(Was: #12) |
0.0 | -89,702 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-12 of 12 holdings